These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28831853)

  • 1. Defining active progressive multiple sclerosis.
    Sellebjerg F; Börnsen L; Ammitzbøll C; Nielsen JE; Vinther-Jensen T; Hjermind LE; von Essen M; Ratzer RL; Soelberg Sørensen P; Romme Christensen J
    Mult Scler; 2017 Nov; 23(13):1727-1735. PubMed ID: 28831853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Role of CHI3L1+ Astrocytes in Progression in MS.
    Cubas-Núñez L; Gil-Perotín S; Castillo-Villalba J; López V; Solís Tarazona L; Gasqué-Rubio R; Carratalá-Boscá S; Alcalá-Vicente C; Pérez-Miralles F; Lassmann H; Casanova B
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33658322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
    Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
    Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
    Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
    Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
    Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 11. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis.
    Modvig S; Degn M; Horwitz H; Cramer SP; Larsson HB; Wanscher B; Sellebjerg F; Frederiksen JL
    PLoS One; 2013; 8(10):e77163. PubMed ID: 24116216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D
    PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.
    Ragheb S; Li Y; Simon K; VanHaerents S; Galimberti D; De Riz M; Fenoglio C; Scarpini E; Lisak R
    Mult Scler; 2011 Jul; 17(7):819-29. PubMed ID: 21372118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.